Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Department of Justice
McKinsey
Fuji
Fish and Richardson
McKesson
Healthtrust
Johnson and Johnson
Cerilliant
Argus Health
AstraZeneca

Generated: October 19, 2017

DrugPatentWatch Database Preview

Novartis Pharms Company Profile

« Back to Dashboard

What is the competitive landscape for NOVARTIS PHARMS, and what generic alternatives to NOVARTIS PHARMS drugs are available?

NOVARTIS PHARMS has seventy approved drugs.

There are one hundred and nineteen US patents protecting NOVARTIS PHARMS drugs and there have been six Paragraph IV challenges on NOVARTIS PHARMS drugs in the past three years.

There are one thousand eight hundred and nineteen patent family members on NOVARTIS PHARMS drugs in seventy-two countries and one hundred and sixty-one supplementary protection certificates in fifteen countries.

Summary for Applicant: Novartis Pharms

International Patents:1819
US Patents:119
Tradenames:60
Ingredients:50
NDAs:70
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novartis Pharms Corp
MOXEZA
moxifloxacin hydrochloride
SOLUTION/DROPS;OPHTHALMIC022428-001Nov 19, 2010AT2RXYesYes► Subscribe► SubscribeY ► Subscribe
Novartis Pharms Corp
PROMACTA
eltrombopag olamine
FOR SUSPENSION;ORAL207027-001Aug 24, 2015RXYesYes► Subscribe► SubscribeY► Subscribe
Novartis Pharms Corp
PROMACTA
eltrombopag olamine
TABLET;ORAL022291-003Sep 8, 2009RXYesYes► Subscribe► SubscribeY► Subscribe
Novartis Pharms Corp
TAFINLAR
dabrafenib mesylate
CAPSULE;ORAL202806-001May 29, 2013RXYesNo► Subscribe► Subscribe► Subscribe
Novartis Pharms Corp
PROMACTA
eltrombopag olamine
TABLET;ORAL022291-004Oct 20, 2011RXYesNo► Subscribe► SubscribeY► Subscribe
Novartis Pharms Corp
PATADAY
olopatadine hydrochloride
SOLUTION/DROPS;OPHTHALMIC021545-001Dec 22, 2004ATRXYesYes► Subscribe► SubscribeY► Subscribe
Novartis Pharms Corp
TAFINLAR
dabrafenib mesylate
CAPSULE;ORAL202806-002May 29, 2013RXYesYes► Subscribe► Subscribe ► Subscribe
Novartis Pharms Corp
PROMACTA
eltrombopag olamine
TABLET;ORAL022291-001Nov 20, 2008RXYesNo► Subscribe► SubscribeY► Subscribe
Novartis Pharms Corp
SIGNIFOR LAR
pasireotide pamoate
POWDER;INTRAMUSCULAR203255-001Dec 15, 2014RXYesNo► Subscribe► Subscribe► Subscribe
Novartis Pharms Corp
PROMACTA
eltrombopag olamine
TABLET;ORAL022291-002Nov 20, 2008RXYesNo► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Novartis Pharms

Paragraph IV activity for NOVARTIS PHARMS drugs

Drugname Dosage Strength Tradename Submissiondate
deferasirox
Tablets180 mg
JADENU
4/28/2016
travoprost
Ophthalmic Solution0.003%
IZBA
12/30/2015
nepafenac
Ophthalmic Suspension0.3%
ILEVRO
12/21/2015
deferasirox
Tablets180 mg
JADENU
10/23/2015
deferasirox
Tablets90 mg and 360 mg
JADENU
10/19/2015
olopatadine hydrochloride
Ophthalmic Solution0.7%
PAZEO
9/10/2015
difluprednate
Ophthalmic Emulsion0.05%
DUREZOL
5/1/2014
eltrombopag olamine
Tablets12.5 mg and 25 mg
PROMACTA
2/4/2014
eltrombopag olamine
Tablets50 mg and 75 mg
PROMACTA
1/7/2014
ciprofloxacin and dexamethasone
Otic Suspension0.3%/0.1%
CIPRODEX
7/31/2012
moxifloxacin hydrochloride
Ophthalmic Solution10.5%
MOXEZA
2/29/2012
argatroban in sodium chloride
Injection1 mg/mL, 50 mL vials
ARGATROBAN
12/16/2011
lapatinib ditosylate
Tablets250 mg
TYKERB
3/14/2011
olopatadine hydrochloride
Nasal Spray0.665 mg/ Spray
PATANASE
6/29/2009
tobramycin
Inhalation Solution300 mg/5 mL
TOBI
6/29/2009
travoprost (preserved)
Ophthalmic Solution0.00%
TRAVATAN Z
2/19/2009
olopatadine hydrochloride
Ophthalmic Solution0.20%
PATADAY
9/8/2008
argatroban
Injection100 mg/mL, 2.5 mL vials
ARGATROBAN
9/24/2007
olopatadine hydrochloride
Ophthalmic Solution0.10%
PATANOL
7/17/2006
letrozole
Tablets2.5 mg
FEMARA
3/2/2006
moxifloxacin hydrochloride
Ophthalmic0.50%
VIGAMOX
12/22/2005
ondansetron hydrochloride
Oral Solution4 mg/5 mL
ZOFRAN
12/20/2004

Non-Orange Book Patents for Novartis Pharms

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,825,116N2, N4-bis-aryl-5-fluoro-2,4-pyrimidinediamines► Subscribe
8,557,806Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds► Subscribe
7,754,733Crystalline topotecan hydrochloride product and process for making the same► Subscribe
6,486,138 Ophthalmic compositions containing galactomannan polymers and borate► Subscribe
8,334,2962,4-pyrimidinediamine compounds and their uses► Subscribe
9,346,7652,4-pyrimidinediamine compounds and their uses► Subscribe
7,858,626Pyrimidineamines as angiogenesis modulators► Subscribe
9,499,4932,4-pyrimidinediamine compounds and their uses► Subscribe
7,812,029Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds► Subscribe
7,557,2102,4-pyrimidinediamine compounds and their uses► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Novartis Pharms Drugs

Country Document Number Estimated Expiration
Taiwan200820962► Subscribe
China1446229► Subscribe
Norway2016009► Subscribe
Spain2409885► Subscribe
San MarinoT201500300► Subscribe
Hong Kong1134290► Subscribe
Guatemala200900147► Subscribe
Iceland5549► Subscribe
Portugal2281563► Subscribe
Portugal1214056► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Novartis Pharms Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
00540Netherlands► SubscribePRODUCT NAME: TRAVOPROST; REGISTRATION NO/DATE: EU/1/01/199/001-002 20011127
C0053Belgium► SubscribePRODUCT NAME: LETROZOLE; NAT. REGISTRATION NO/DATE: 206 IS 241 F 3 19970616; FIRST REGISTRATION: FR 341 474.2 1996072
C0045France► SubscribePRODUCT NAME: TRAVOPROST; REGISTRATION NO/DATE: EU/1/01/199/001 20011127
C/GB10/026United Kingdom► SubscribePRODUCT NAME: ELTROMBOPAG, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE (INCLUDING A HYDRATE); REGISTERED: UK EU1/10/612/001 20100311; UK EU1/10/612/002 20100311; UK EU1/10/612/003 20100311; UK EU1/10/612/004 20100311; UK EU1/10/612/005 20100311; UK EU1/10/612/006 20100311
2010 00024Denmark► Subscribe
0360Netherlands► SubscribeDETAILS ASSIGNMENT: VERANDERING VAN EIGENAAR(S), OVERDRACHT
2012 00024Denmark► SubscribePRODUCT NAME: PASIREOTID OG FARMACEUTISK ACCEPTABLE SALTE DERAF, HERUNDER PASIREOTIDDIASPARTAT; REG. NO/DATE: EU/1/12/753/001-012 20120424
9Finland► Subscribe
C0049France► SubscribePRODUCT NAME: DEFERASIROX OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; REGISTRATION NO/DATE IN FRANCE: EU/1/06/356/001 DU 20060828; REGISTRATION NO/DATE AT EEC: EU/1/06/356/001 DU 20060828
024Luxembourg► Subscribe92024, EXPIRES: 20260730
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
Deloitte
Chinese Patent Office
Cipla
US Department of Justice
UBS
Colorcon
Farmers Insurance
McKinsey
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot